Navigation Links
New Study Reveals that PEEK Polymer Spinal Cage Is Superior to Titanium in Surgical Treatment of Multilevel Cervical Spondylotic Myelopathy
Date:6/24/2013

Shanghai, China (PRWEB) June 24, 2013

A seven year clinical study has concluded that a cage made of the high performance PEEK polymer is superior to a Titanium cage in maintenance of intervertebral height and cervical lordosis in surgical treatment of multilevel cervical spondylotic myelopathy (CSM). According to the study, published in the European Spine Journal this results in better clinical outcomes in long-term follow-up. The randomized study with a total of 80 patients includes an average follow-up period of around 7 years.

In the treatment of CSM anterior cervical discectomy and fusion (ACDF) with titanium- or polyetheretherketone (PEEK)-cage reconstruction is typically used. Titanium implants offer structural properties that are likely to provide a good immediate stability and osseointegration, whilst PEEK cages have a modulus of elasticity closely resembling that of cortical bone, which might lead to advantages in load sharing and stress distribution. Until now a direct comparison of titanium and PEEK cages in the treatment of cervical disc degeneration disease is rarely found in literature.

Dr Chen Y and colleagues from the Department of Spine Surgery, Changzhen Hospital, Shanghai, designed the study to compare outcomes of titanium and PEEK cages. A total of 80 patients with 3-level CSM were randomized in a 1:1 ratio into two groups between November 2002 and December 2004. The overall follow-up period of the patients ranged from 86 to 116 months (average 99.7 months).

The clinical outcomes including JOA (Japanese Orthopedic Association) score, NDI (Neck Disability Index) score demonstrate that patients benefit from cages made of implantable PEEK polymer. “Although fusion was observed in all patients of two groups at the final follow-up, the Titanium group demonstrated significantly inferior clinical outcomes compared to the PEEK group. More loss of the Cobb angles, measurement of spine curvature, and the intervertebral height was observed in the titanium group, resulting in the radiological parameters in the titanium group becoming inferior to the PEEK group at the final follow-up. Cage subsidence rates were 34.5 % in the titanium and 5.4 % in the PEEK group. The higher modulus of the titanium material properties, is the likely cause of this.” The research team comments on the results of the study.

About Changzheng Hospital
Established in 1900, Shanghai Changzheng hospital is a comprehensive Three A hospital in Shanghai, which combines medical, educational and scientific research functions.

The number of spinal procedures carried out at the hospital is increasingly growing, the cervical procedures broke through 25,000 cases, among which, the highly difficult occipital cervical procedures exceed 3000 cases. The hospital builds up its specialities in the treatment of cervical spondylopathy, lumbar degenerative disc disease, upper cervical disease, spinal trauma, spinal minimally invasive surgery, etc., this positions the Shanghai Changzheng hospital as the leading hospital in this field.

Shanghai Changzheng hospital is strong in both expertise and hardware facilities, it has been awarded as the advanced hospital in China on a number of occasions and has cultivated a vast number of excellent medical experts for the nation.

Read the full story at http://www.prweb.com/releases/2013/6/prweb10848608.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Positive Clinical Study Results for BSPs HyperQ Technology
2. 15-Minute Data From Phase 3 Study of Avanafil Featured as a Late Breaking Abstract at SMSNA Annual Meeting
3. DermTechs Non-invasive Melanoma Detection Assay Poised to Enter Clinical Validation Study
4. Marshall study shows nanoparticles used as additives in diesel fuels can travel from lungs to liver
5. Clionsky Neuro Systems (CNS-Neuro) Announces Publication of Study Finding Elderly Patients Unable to Recognize Their Memory Loss
6. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
7. AtheroNova Inc. Preclinical Study Demonstrates 95% Reduction in Arterial Plaque Formation
8. Singapore scientists lead human embryonic stem cell study
9. GeneTex Antibody Company to Launch New Line of Primary Antibodies for the Study of Spindle Assembly
10. Nutra Pharma Announces Publication of a New Mechanism Study of Alpha-Cobratoxin in the Treatment of Pain
11. Metabolex Announces Positive Results From its Clinical Study of Arhalofenate in Combination With Febuxostat
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2018)... (PRWEB) , ... July 27, ... ... and Renewable Products Advocacy Group (BRAG®) and representatives of the Biotechnology Innovation ... the two groups’ recently-issued white paper, “Proposal for a Toxic Substances Control ...
(Date:7/25/2018)... ... July 25, 2018 , ... Dimitrius Anagnos, an evidence-based healer, ... inflammation and autoimmune disorders. , The preclinical research assessed biomarkers for systemic ... reported:, Over 70% decrease in Interleukin (IL-1ß) expression ...
(Date:7/25/2018)... , ... July 25, 2018 , ... ... for managing clinical trial patient and supplies data through its flagship IXRS® ... on IRT: Best Practices.” , This podcast features both Almac thought leaders and ...
(Date:7/24/2018)... ... ... R3 Stem Cell is now offering regenerative therapies for COPD lung disease ... Certified providers, with outcomes significantly improving patient quality of life. , Traditional therapies for ... help repair and regenerate damaged lung tissues. Stem cell therapy for COPD ...
Breaking Biology Technology:
(Date:8/7/2018)... ... August 07, 2018 , ... ... and biotherapeutics development, announces a new publication titled, “Synthetic Molecules for Disruption ... Chemistry. The paper prominently features use of Agile R100, described as a “ ...
(Date:8/2/2018)... ... August 02, 2018 , ... The American College of Lifestyle ... to its Lifestyle Medicine Corporate Roundtable, a group of individuals and organizations whose ... sustainable world. , Boston Heart is transforming the treatment of cardiovascular disease ...
(Date:8/1/2018)... ... August 01, 2018 , ... RURO, Inc., ... Limfinity® version 7.1. Limfinity® is the software framework that all of RURO’s products ... for both current users and the future of RURO’s laboratory software portfolio. , ...
Breaking Biology News(10 mins):